Merck Sharp & Dohme (MSD) has officially launched its innovative cephalosporin inhibitor combination, Cefiderocol Tazobactam Sodium for Injection, under the brand name Zolida® in China. This drug is specifically formulated to address drug-resistant infections caused by bacteria such as Pseudomonas aeruginosa and extended-spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae. It received approval from China's National Medical Products Administration (NMPA) in February 2025.

Zolida® is indicated for the treatment of a range of serious infections, including complicated intra-abdominal infections, complicated urinary tract infections, hospital-acquired bacterial pneumonia, and ventilator-associated bacterial pneumonia. In light of the escalating challenge posed by drug-resistant Gram-negative bacterial infections in recent years, Zolida® has shown promising results in clinical trials, demonstrating potent antibacterial activity with a low likelihood of resistance induction. This makes Zolida® a highly anticipated new treatment option for patients suffering from drug-resistant infections.